NASDAQ:DMPI - DelMar Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.99 +0.02 (+2.06 %)
(As of 05/21/2018 03:08 AM ET)
Previous Close$0.99
Today's Range$0.9557 - $0.9971
52-Week Range$0.78 - $2.84
Volume41,503 shs
Average Volume121,685 shs
Market Capitalization$21.71 million
P/E Ratio-1.34
Dividend YieldN/A
Beta1.46

About DelMar Pharmaceuticals (NASDAQ:DMPI)

DelMar Pharmaceuticals logoDelMar Pharmaceuticals, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. Its product candidate includes VAL-083, a small-molecule chemotherapeutic agent, which is in Phase III study for the treatment of recurrent glioblastoma multiforme. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical Company for the manufacture and sale of VAL-083 in China; collaboration agreement with the University of Texas MD Anderson Cancer Center; and collaboration agreement with Accurexa Inc. to develop a novel formulation for the combined local delivery of VAL-083 and temozolomide. DelMar Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Vancouver, Canada.

Receive DMPI News and Ratings via Email

Sign-up to receive the latest news and ratings for DMPI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:DMPI
CUSIPN/A
Phone604-629-5989

Debt

Debt-to-Equity RatioN/A
Current Ratio4.80
Quick Ratio5.49

Price-To-Earnings

Trailing P/E Ratio-1.34
Forward P/E Ratio-2.15
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.06 per share
Price / Book16.50

Profitability

EPS (Most Recent Fiscal Year)($0.74)
Net Income$-8,080,000.00
Net MarginsN/A
Return on Equity-397.62%
Return on Assets-102.75%

Miscellaneous

Employees15
Outstanding Shares21,930,000

DelMar Pharmaceuticals (NASDAQ:DMPI) Frequently Asked Questions

What is DelMar Pharmaceuticals' stock symbol?

DelMar Pharmaceuticals trades on the NASDAQ under the ticker symbol "DMPI."

When did DelMar Pharmaceuticals' stock split? How did DelMar Pharmaceuticals' stock split work?

DelMar Pharmaceuticals's stock reverse split on the morning of Friday, May 20th 2016. The 1-4 reverse split was announced on Thursday, May 19th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 19th 2016. An investor that had 100 shares of DelMar Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.

How were DelMar Pharmaceuticals' earnings last quarter?

DelMar Pharmaceuticals (NASDAQ:DMPI) issued its quarterly earnings results on Tuesday, May, 15th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.03. View DelMar Pharmaceuticals' Earnings History.

What price target have analysts set for DMPI?

3 analysts have issued 12 month target prices for DelMar Pharmaceuticals' shares. Their forecasts range from $11.00 to $12.00. On average, they anticipate DelMar Pharmaceuticals' stock price to reach $11.50 in the next twelve months. View Analyst Ratings for DelMar Pharmaceuticals.

What are Wall Street analysts saying about DelMar Pharmaceuticals stock?

Here are some recent quotes from research analysts about DelMar Pharmaceuticals stock:
  • 1. HC Wainwright analysts commented, "Ovarian Cancer Role for VAL-083; Reiterate Buy Stock Data 10/13/2017 Price $0.88 Exchange NASDAQ Price Target $12.00 52-Week High $5.77 52-Week Low $0.80 Enterprise Value (M) $12.4 Market Cap (M) $19 Public Market Float (M) 19.3 Shares Outstanding (M) 21.6 3 Month Avg Volume 959,521 Short Interest (M) 0.35 Balance Sheet Metrics Cash (M) $6.59 Total Debt (M) $0.00 Total Cash/Share $0.31 Book Value/Share $(0.09) EPS Diluted Full Year – Jun 2016A 2017A 2018E 1Q (0.15) (0.23) (0.17) 2Q (0.24) (0.13) (0.16) 3Q (0.10) (0.18) (0.14) 4Q (0.31) (0.20) (0.12) FY (0.81) (0.74) (0.57) 6 5 4 3 2 1 0 OCT- 16 FEB- 17 J UN- 17 OCT- 17 40 30 20 10 0 Vol. (mil) Price Continuing coverage under the name H.C. Wainwright & Co. with a Buy rating. Effective October 5, 2017, research in the above titled name will now be published under H.C. Wainwright & Co. and no longer distributed in conjunction with ‘Rodman & Renshaw, a unit of H.C." (10/16/2017)
  • 2. Maxim Group analysts commented, "Delmar announced news of another Phase II trial (biomarker driven), N=20-30 in newly diagnosed MGMT-unmethylated glioblastoma multiforme (GBM). The trial will be funded by Guangxi Wuzhou Pharmaceutical Group Co. (private). Management states that data is expected 9-15 months from the time the trial begins." (9/11/2017)

Who are some of DelMar Pharmaceuticals' key competitors?

Who are DelMar Pharmaceuticals' key executives?

DelMar Pharmaceuticals' management team includes the folowing people:
  • Mr. Saiid Zarrabian B.Sc., MBA, Interim Pres, Interim CEO & Director (Age 65)
  • Mr. Jeffrey A. Bacha, Founder (Age 50)
  • Dr. Dennis M. Brown, Co-Founder & Chief Scientific Officer (Age 69)
  • Mr. Scott Praill, CFO & Sec. (Age 51)
  • Dr. Victor Levin M.D., Advisor

Has DelMar Pharmaceuticals been receiving favorable news coverage?

News stories about DMPI stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. DelMar Pharmaceuticals earned a news impact score of 0.06 on Accern's scale. They also gave news stories about the company an impact score of 47.11 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

How do I buy shares of DelMar Pharmaceuticals?

Shares of DMPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is DelMar Pharmaceuticals' stock price today?

One share of DMPI stock can currently be purchased for approximately $0.99.

How big of a company is DelMar Pharmaceuticals?

DelMar Pharmaceuticals has a market capitalization of $21.71 million. The company earns $-8,080,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis. DelMar Pharmaceuticals employs 15 workers across the globe.

How can I contact DelMar Pharmaceuticals?

DelMar Pharmaceuticals' mailing address is SUITE 720-999 WEST BROADWAY, VANCOUVER A1, V5Z 1K5. The company can be reached via phone at 604-629-5989 or via email at [email protected]


MarketBeat Community Rating for DelMar Pharmaceuticals (DMPI)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  121 (Vote Outperform)
Underperform Votes:  74 (Vote Underperform)
Total Votes:  195
MarketBeat's community ratings are surveys of what our community members think about DelMar Pharmaceuticals and other stocks. Vote "Outperform" if you believe DMPI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DMPI will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

DelMar Pharmaceuticals (NASDAQ:DMPI) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for DelMar Pharmaceuticals in the last 12 months. Their average twelve-month price target is $11.50, suggesting that the stock has a possible upside of 1,061.62%. The high price target for DMPI is $12.00 and the low price target for DMPI is $11.00. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.672.672.75
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $11.50$11.50$11.50$13.00
Price Target Upside: 1,061.62% upside709.86% upside709.86% upside1,384.02% upside

DelMar Pharmaceuticals (NASDAQ:DMPI) Consensus Price Target History

Price Target History for DelMar Pharmaceuticals (NASDAQ:DMPI)

DelMar Pharmaceuticals (NASDAQ:DMPI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/4/2018HC WainwrightSet Price TargetBuy$12.00MediumView Rating Details
9/11/2017Maxim GroupReiterated RatingHoldHighView Rating Details
8/8/2017Dawson JamesReiterated RatingBuyHighView Rating Details
1/5/2017AegisInitiated CoverageBuy$16.00N/AView Rating Details
7/18/2016Rodman & RenshawReiterated RatingBuyN/AView Rating Details
(Data available from 5/21/2016 forward)

Earnings

DelMar Pharmaceuticals (NASDAQ:DMPI) Earnings History and Estimates Chart

Earnings by Quarter for DelMar Pharmaceuticals (NASDAQ:DMPI)

DelMar Pharmaceuticals (NASDAQ:DMPI) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.46 EPS
Next Year EPS Consensus Estimate: $-0.26 EPS

DelMar Pharmaceuticals (NASDAQ DMPI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/15/2018Q3($0.10)($0.13)ViewN/AView Earnings Details
2/15/2018Before Market($0.15)($0.14)ViewN/AView Earnings Details
11/13/2017($0.17)($0.18)ViewN/AView Earnings Details
9/27/2017Q4 2017($0.19)($0.20)ViewN/AView Earnings Details
5/18/2017($0.18)($0.18)ViewN/AView Earnings Details
2/10/201712/31/2016($0.22)($0.13)ViewN/AView Earnings Details
11/10/20169/30/2016($0.15)($0.23)ViewN/AView Earnings Details
9/13/2016Q4 2016($0.17)($0.17)ViewN/AView Earnings Details
5/12/2016Q3 2016($0.16)($0.12)ViewN/AView Earnings Details
2/16/2016Q2 16($0.03)($0.06)ViewN/AView Earnings Details
11/16/2015Q1 2016($0.12)($0.16)ViewN/AView Earnings Details
9/4/2015Q4 2015($0.09)($0.02)ViewN/AView Earnings Details
5/15/2015Q3 2015($0.07)($0.04)ViewN/AView Earnings Details
2/12/2015Q2 2015($0.06)($0.03)ViewN/AView Earnings Details
11/10/2014Q1 2015($0.07)($0.04)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

DelMar Pharmaceuticals (NASDAQ:DMPI) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

DelMar Pharmaceuticals (NASDAQ DMPI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 12.20%
Institutional Ownership Percentage: 5.65%
Insider Trading History for DelMar Pharmaceuticals (NASDAQ:DMPI)
Insider Trading History for DelMar Pharmaceuticals (NASDAQ:DMPI)

DelMar Pharmaceuticals (NASDAQ DMPI) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/16/2017John K BellDirectorBuy20,000$0.81$16,200.00View SEC Filing  
11/14/2017Saiid ZarrabianCEOBuy60,900$0.82$49,938.00View SEC Filing  
10/6/2017Jeffrey BachaCEOBuy10,000$0.87$8,700.00View SEC Filing  
10/5/2017Scott PraillInsiderBuy17,500$0.85$14,875.00View SEC Filing  
6/26/2017Jeffrey BachaCEOBuy6,700$3.60$24,120.0053,345View SEC Filing  
6/26/2017John K BellDirectorBuy4,167$3.60$15,001.20View SEC Filing  
6/6/2017Jeffrey BachaCEOBuy5,000$2.12$10,600.0046,645View SEC Filing  
6/6/2017John K BellDirectorBuy10,000$2.12$21,200.00View SEC Filing  
6/6/2017Scott PraillCFOBuy9,500$2.10$19,950.0025,277View SEC Filing  
5/5/2017Jeffrey BachaCEOBuy2,500$2.20$5,500.0041,645View SEC Filing  
2/1/2017Jeffrey BachaCEOBuy4,000$5.00$20,000.0038,969View SEC Filing  
11/25/2015Jeffrey BachaCEOBuy7,500$1.47$11,025.00137,985View SEC Filing  
10/8/2015Jeffrey BachaCEOBuy3,000$0.80$2,400.00130,485View SEC Filing  
9/18/2015Jeffrey BachaCEOBuy4,000$0.83$3,320.00127,485View SEC Filing  
7/22/2015Dennis M BrownMajor ShareholderBuy75,000$0.60$45,000.00View SEC Filing  
7/16/2015Jeffrey BachaCEOBuy50,000$0.60$30,000.00View SEC Filing  
7/16/2015William J GarnerDirectorBuy16,666$0.60$9,999.60View SEC Filing  
1/22/2015Jeffrey BachaCEOBuy7,500$0.66$4,950.00View SEC Filing  
12/9/2014Jeffrey BachaCEOBuy2,500$0.90$2,250.00View SEC Filing  
11/26/2014Jeffrey BachaCEOBuy2,500$0.92$2,300.00View SEC Filing  
11/21/2014John K BellDirectorBuy8,000$0.95$7,600.00View SEC Filing  
9/18/2014Jeffrey BachaCEOBuy4,000$0.98$3,920.00View SEC Filing  
9/15/2014Jeffrey BachaCEOBuy4,985$0.75$3,738.75View SEC Filing  
9/8/2014John K BellDirectorBuy7,000$0.71$4,970.00View SEC Filing  
9/4/2014John K BellDirectorBuy8,000$0.78$6,240.00View SEC Filing  
4/22/2014John K BellDirectorBuy20,000$1.25$25,000.00View SEC Filing  
3/18/2014Dennis M BrownMajor ShareholderBuy10,000$1.30$13,000.00View SEC Filing  
3/18/2014Robert Joseph Toth JrDirectorBuy25,000$1.30$32,500.00View SEC Filing  
3/4/2014Dennis M BrownMajor ShareholderBuy5,000$1.56$7,800.00View SEC Filing  
2/21/2014Jeffrey BachaCEOBuy5,000$1.00$5,000.00View SEC Filing  
2/13/2014Jeffrey BachaCEOBuy5,000$0.80$4,000.00View SEC Filing  
2/11/2014John K BellDirectorBuy9,000$0.83$7,470.00View SEC Filing  
2/5/2014Robert Joseph Toth JrDirectorBuy9,000$0.88$7,920.00View SEC Filing  
1/31/2014Robert Joseph Toth JrDirectorBuy2,000$0.87$1,740.00View SEC Filing  
1/29/2014Robert Joseph Toth JrDirectorBuy7,500$0.91$6,825.00View SEC Filing  
9/20/2013William J GarnerDirectorBuy5,000$1.00$5,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

DelMar Pharmaceuticals (NASDAQ DMPI) News Headlines

Source:
DateHeadline
DelMar Pharmaceuticals (DMPI) Expected to Post Earnings of -$0.08 Per ShareDelMar Pharmaceuticals (DMPI) Expected to Post Earnings of -$0.08 Per Share
www.americanbankingnews.com - May 19 at 11:15 PM
 DelMar Pharmaceuticals (DMPI) Given $11.16 Consensus Price Target by Brokerages DelMar Pharmaceuticals (DMPI) Given $11.16 Consensus Price Target by Brokerages
www.americanbankingnews.com - May 18 at 11:46 AM
DelMar Pharmaceuticals (DMPI) Posts Quarterly  Earnings Results, Misses Expectations By $0.03 EPSDelMar Pharmaceuticals (DMPI) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS
www.americanbankingnews.com - May 17 at 10:46 AM
DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2018 Financial ResultsDelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2018 Financial Results
www.prnewswire.com - May 17 at 5:49 AM
 DelMar Pharmaceuticals (DMPI) Given $11.16 Average Price Target by Analysts DelMar Pharmaceuticals (DMPI) Given $11.16 Average Price Target by Analysts
www.americanbankingnews.com - May 2 at 11:19 PM
 Analysts Expect DelMar Pharmaceuticals (DMPI) Will Post Earnings of -$0.10 Per Share Analysts Expect DelMar Pharmaceuticals (DMPI) Will Post Earnings of -$0.10 Per Share
www.americanbankingnews.com - May 2 at 11:24 AM
Reviewing DelMar Pharmaceuticals (DMPI) & Its RivalsReviewing DelMar Pharmaceuticals (DMPI) & Its Rivals
www.americanbankingnews.com - May 1 at 1:04 PM
Delmar Pharma (DMPI) Presents Positive Updates on Two Ongoing Clinical Trials with VAL-083 for Treatment of MGMT-unmethylated GBMDelmar Pharma (DMPI) Presents Positive Updates on Two Ongoing Clinical Trials with VAL-083 for Treatment of MGMT-unmethylated GBM
www.streetinsider.com - April 27 at 5:28 PM
DelMar Pharmaceuticals Presents Positive Updates on Two Ongoing Clinical Trials with VAL-083 for Treatment of MGMT-unmethylated GBMDelMar Pharmaceuticals Presents Positive Updates on Two Ongoing Clinical Trials with VAL-083 for Treatment of MGMT-unmethylated GBM
finance.yahoo.com - April 17 at 5:39 PM
 DelMar Pharmaceuticals (DMPI) Given $11.16 Consensus Target Price by Analysts DelMar Pharmaceuticals (DMPI) Given $11.16 Consensus Target Price by Analysts
www.americanbankingnews.com - April 16 at 9:25 AM
DelMar Pharmaceuticals Announces Multiple Presentations at Annual Meeting of the American Association for Cancer ResearchDelMar Pharmaceuticals Announces Multiple Presentations at Annual Meeting of the American Association for Cancer Research
finance.yahoo.com - April 16 at 9:09 AM
BRIEF-Delmar Pharmaceuticals To Increase Number Of Authorized Shares Of Stock, Par Value Of $0.001, Per Share ...BRIEF-Delmar Pharmaceuticals To Increase Number Of Authorized Shares Of Stock, Par Value Of $0.001, Per Share ...
www.reuters.com - April 15 at 5:43 PM
-$0.10 Earnings Per Share Expected for DelMar Pharmaceuticals (DMPI) This Quarter-$0.10 Earnings Per Share Expected for DelMar Pharmaceuticals (DMPI) This Quarter
www.americanbankingnews.com - April 15 at 11:15 AM
HC Wainwright Reiterates $12.00 Price Target for DelMar Pharmaceuticals (DMPI)HC Wainwright Reiterates $12.00 Price Target for DelMar Pharmaceuticals (DMPI)
www.americanbankingnews.com - April 7 at 10:18 AM
Reviewing DelMar Pharmaceuticals (DMPI) and Its CompetitorsReviewing DelMar Pharmaceuticals (DMPI) and Its Competitors
www.americanbankingnews.com - April 2 at 7:12 PM
DelMar Pharmaceuticals (DMPI) Given a $12.00 Price Target by HC Wainwright AnalystsDelMar Pharmaceuticals (DMPI) Given a $12.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - March 30 at 3:58 PM
Zacks: DelMar Pharmaceuticals Inc (DMPI) Given Consensus Recommendation of "Buy" by BrokeragesZacks: DelMar Pharmaceuticals Inc (DMPI) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 30 at 1:21 PM
Zacks: DelMar Pharmaceuticals Inc (DMPI) Receives Average Recommendation of "Buy" from AnalystsZacks: DelMar Pharmaceuticals Inc (DMPI) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 16 at 3:20 PM
Zacks: Analysts Anticipate DelMar Pharmaceuticals Inc (DMPI) Will Announce Earnings of -$0.10 Per ShareZacks: Analysts Anticipate DelMar Pharmaceuticals Inc (DMPI) Will Announce Earnings of -$0.10 Per Share
www.americanbankingnews.com - March 12 at 11:22 AM
Today’s Research Reports on Stocks to Watch: Lipocine and DelMar PharmaceuticalsToday’s Research Reports on Stocks to Watch: Lipocine and DelMar Pharmaceuticals
finance.yahoo.com - February 28 at 8:44 AM
DelMar Pharmaceuticals Inc (DMPI) Expected to Post Earnings of -$0.13 Per ShareDelMar Pharmaceuticals Inc (DMPI) Expected to Post Earnings of -$0.13 Per Share
www.americanbankingnews.com - February 23 at 2:20 PM
DelMar Pharmaceuticals (DMPI) Management on Q2 2018 Results ... - Seeking AlphaDelMar Pharmaceuticals' (DMPI) Management on Q2 2018 Results ... - Seeking Alpha
seekingalpha.com - February 22 at 8:11 AM
 Analysts Set $11.16 Price Target for DelMar Pharmaceuticals Inc (DMPI) Analysts Set $11.16 Price Target for DelMar Pharmaceuticals Inc (DMPI)
www.americanbankingnews.com - February 19 at 1:16 AM
DelMar Pharmaceuticals (DMPI) Issues  Earnings ResultsDelMar Pharmaceuticals (DMPI) Issues Earnings Results
www.americanbankingnews.com - February 15 at 11:40 AM
DelMar Pharmaceuticals Announces Second Quarter Fiscal Year ... - PR Newswire (press release)DelMar Pharmaceuticals Announces Second Quarter Fiscal Year ... - PR Newswire (press release)
www.prnewswire.com - February 15 at 7:24 AM
DelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2018 Financial ResultsDelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2018 Financial Results
finance.yahoo.com - February 15 at 7:24 AM
Is DelMar Pharmaceuticals Inc (NASDAQ:DMPI) A Healthcare Industry Laggard Or Leader?Is DelMar Pharmaceuticals Inc (NASDAQ:DMPI) A Healthcare Industry Laggard Or Leader?
finance.yahoo.com - February 14 at 3:32 PM
Zacks: Analysts Set $11.16 Price Target for DelMar Pharmaceuticals Inc (DMPI)Zacks: Analysts Set $11.16 Price Target for DelMar Pharmaceuticals Inc (DMPI)
www.americanbankingnews.com - February 10 at 7:14 PM
Zacks: DelMar Pharmaceuticals Inc (DMPI) Given Average Recommendation of "Buy" by AnalystsZacks: DelMar Pharmaceuticals Inc (DMPI) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - February 5 at 10:24 AM
DelMar Pharmaceuticals (DMPI) Scheduled to Post Earnings on MondayDelMar Pharmaceuticals (DMPI) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - February 5 at 3:26 AM
 Analysts Expect DelMar Pharmaceuticals Inc (DMPI) to Post -$0.15 Earnings Per Share Analysts Expect DelMar Pharmaceuticals Inc (DMPI) to Post -$0.15 Earnings Per Share
www.americanbankingnews.com - January 20 at 3:28 PM
 DelMar Pharmaceuticals Inc (DMPI) Receives Average Rating of "Buy" from Brokerages DelMar Pharmaceuticals Inc (DMPI) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - January 19 at 9:32 AM
Zacks: DelMar Pharmaceuticals Inc (DMPI) Given Consensus Rating of "Buy" by BrokeragesZacks: DelMar Pharmaceuticals Inc (DMPI) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - January 15 at 5:08 PM
Zacks: DelMar Pharmaceuticals Inc (DMPI) Receives Consensus Rating of "Buy" from AnalystsZacks: DelMar Pharmaceuticals Inc (DMPI) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - January 9 at 11:16 PM
DelMar Pharmaceuticals stock rockets after cancer treatment granted Fast Track designation - MarketWatchDelMar Pharmaceuticals' stock rockets after cancer treatment granted 'Fast Track' designation - MarketWatch
www.marketwatch.com - December 28 at 8:18 AM
A Peek Into The Markets: US Stock Futures Down; Mallinckrodt To Acquire Sucampo Pharmaceuticals - BenzingaA Peek Into The Markets: US Stock Futures Down; Mallinckrodt To Acquire Sucampo Pharmaceuticals - Benzinga
www.benzinga.com - December 26 at 9:06 AM
Delmar Pharma (DMPI) Gramted Fast Track Designation for VAL ... - StreetInsider.comDelmar Pharma (DMPI) Gramted Fast Track Designation for VAL ... - StreetInsider.com
www.streetinsider.com - December 26 at 9:06 AM
DelMar Pharmaceuticals stock rockets after cancer treatment granted Fast Track designationDelMar Pharmaceuticals' stock rockets after cancer treatment granted 'Fast Track' designation
finance.yahoo.com - December 26 at 9:06 AM
 DelMar Pharmaceuticals, Inc. (DMPI) Receives Consensus Rating of "Buy" from Analysts DelMar Pharmaceuticals, Inc. (DMPI) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - December 22 at 12:20 AM
Should You Be Concerned About DelMar Pharmaceuticals Inc’s (DMPI) Shareholders?Should You Be Concerned About DelMar Pharmaceuticals Inc’s (DMPI) Shareholders?
finance.yahoo.com - December 8 at 5:04 PM
 DelMar Pharmaceuticals, Inc. (DMPI) Given Consensus Recommendation of "Buy" by Analysts DelMar Pharmaceuticals, Inc. (DMPI) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - December 6 at 2:46 PM
Contrasting DelMar Pharmaceuticals (DMPI) and Javelin Mortgage Investment (JMI)Contrasting DelMar Pharmaceuticals (DMPI) and Javelin Mortgage Investment (JMI)
www.americanbankingnews.com - November 30 at 11:24 PM
 Analysts Anticipate DelMar Pharmaceuticals, Inc. (DMPI) Will Post Earnings of -$0.16 Per Share Analysts Anticipate DelMar Pharmaceuticals, Inc. (DMPI) Will Post Earnings of -$0.16 Per Share
www.americanbankingnews.com - November 30 at 1:26 AM
DelMar Pharmaceuticals (DMPI) and Javelin Mortgage Investment (JMI) Financial ComparisonDelMar Pharmaceuticals (DMPI) and Javelin Mortgage Investment (JMI) Financial Comparison
www.americanbankingnews.com - November 29 at 9:44 PM
HC Wainwright Analysts Give DelMar Pharmaceuticals (DMPI) a $12.00 Price TargetHC Wainwright Analysts Give DelMar Pharmaceuticals (DMPI) a $12.00 Price Target
www.americanbankingnews.com - November 29 at 7:30 PM
Javelin Mortgage Investment (JMI) & DelMar Pharmaceuticals (DMPI) Critical ContrastJavelin Mortgage Investment (JMI) & DelMar Pharmaceuticals (DMPI) Critical Contrast
www.americanbankingnews.com - November 27 at 1:38 AM
Reviewing Javelin Mortgage Investment (JMI) & DelMar Pharmaceuticals (DMPI)Reviewing Javelin Mortgage Investment (JMI) & DelMar Pharmaceuticals (DMPI)
www.americanbankingnews.com - November 26 at 1:16 AM
Financial Survey: DelMar Pharmaceuticals (DMPI) and Javelin Mortgage Investment (JMI)Financial Survey: DelMar Pharmaceuticals (DMPI) and Javelin Mortgage Investment (JMI)
www.americanbankingnews.com - November 25 at 5:10 PM
Comparing Javelin Mortgage Investment Corp (JMI) & DelMar Pharmaceuticals (DMPI)Comparing Javelin Mortgage Investment Corp (JMI) & DelMar Pharmaceuticals (DMPI)
www.americanbankingnews.com - November 24 at 5:36 AM
Zacks: DelMar Pharmaceuticals, Inc. (DMPI) Given $11.16 Consensus Target Price by BrokeragesZacks: DelMar Pharmaceuticals, Inc. (DMPI) Given $11.16 Consensus Target Price by Brokerages
www.americanbankingnews.com - November 21 at 11:28 PM

SEC Filings

DelMar Pharmaceuticals (NASDAQ:DMPI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

DelMar Pharmaceuticals (NASDAQ DMPI) Stock Chart for Monday, May, 21, 2018

Loading chart…

This page was last updated on 5/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.